Duloxetine Zentiva

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

duloxetine

Disponible depuis:

Zentiva, k.s.

Code ATC:

N06AX21

DCI (Dénomination commune internationale):

duloxetine

Groupe thérapeutique:

Other antidepressants

Domaine thérapeutique:

Neuralgia; Depressive Disorder, Major; Anxiety Disorders; Diabetes Mellitus

indications thérapeutiques:

Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder. Duloxetine Zentiva is indicated in adults.,

Descriptif du produit:

Revision: 11

Statut de autorisation:

Authorised

Date de l'autorisation:

2015-08-20

Notice patient

                                33
B. PACKAGE LEAFLET
34
PACKAGE LEAFLET: INFORMATION FOR THE USER
DULOXETINE ZENTIVA 30 MG GASTRO-RESISTANT HARD CAPSULES
DULOXETINE ZENTIVA 60 MG GASTRO-RESISTANT HARD CAPSULES
duloxetine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
−
Keep this leaflet. You may need to read it again.
−
If you have any further questions, ask your doctor or pharmacist.
−
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
−
If you get any of the side effects, talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Duloxetine Zentiva is and what it is used for
2.
What you need to know before you take Duloxetine Zentiva
3.
How to take Duloxetine Zentiva
4.
Possible side effects
5.
How to store Duloxetine Zentiva
6.
Contents of the pack and other information
1.
WHAT DULOXETINE ZENTIVA IS AND WHAT IT IS USED FOR
Duloxetine Zentiva contains the active substance duloxetine.
Duloxetine Zentiva increases the levels
of serotonin and noradrenaline in the nervous system.
Duloxetine Zentiva is used in adults to treat:
•
depression;
•
generalised anxiety disorder (chronic feeling of anxiety or
nervousness);
•
diabetic neuropathic pain (often described as burning, stabbing,
stinging, shooting or aching or
like an electric shock. There may be loss of feeling in the affected
area, or sensations such as
touch, heat, cold or pressure may cause pain).
Duloxetine Zentiva starts to work in most people with depression or
anxiety within two weeks of
starting treatment, but it may take 2-4 weeks before you feel better.
Tell your doctor if you do not start
to feel better after this time. Your doctor may continue to give you
Duloxetine Zentiva when you are
feeling better to prevent your depression or anxiety from returning.
In people with diabetic neuropathic pain it can take 
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Duloxetine Zentiva 30 mg gastro-resistant hard capsules
Duloxetine Zentiva 60 mg gastro-resistant hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Duloxetine Zentiva 30 mg gastro-resistant hard capsules
Each capsule contains duloxetine hydrochloride equivalent to 30 mg
duloxetine.
Excipient(s) with known effect
Each capsule contains 42.26 – 46.57 mg of sucrose.
Duloxetine Zentiva 60 mg gastro-resistant hard capsules
Each capsule contains duloxetine hydrochloride equivalent to 60 mg
duloxetine.
Excipient(s) with known effect
Each capsule contains 84.51 - 93.14 mg of sucrose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant hard capsule
Duloxetine Zentiva 30 mg gastro-resistant hard capsules
Hard opaque gelatin capsules of length approx. 15.9 mm with white
opaque body and light-blue
opaque cap which contain off-white to light-brown-yellow spherical
pellets.
Duloxetine Zentiva 60 mg gastro-resistant hard capsules
Hard opaque gelatin capsules of length approx. 19.4 mm with ivory
opaque body and light-blue
opaque cap which contain off-white to light-brown-yellow spherical
pellets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of major depressive disorder.
Treatment of diabetic peripheral neuropathic pain.
Treatment of generalised anxiety disorder.
Duloxetine Zentiva is indicated in adults.
For further information see section 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Major depressive disorder _
The starting and recommended maintenance dose is 60 mg once daily with
or without food. Dosages
above 60 mg once daily, up to a maximum dose of 120 mg per day have
been evaluated from a safety
perspective in clinical trials. However, there is no clinical evidence
suggesting that patients not
responding to the initial recommended dose may benefit from dose
up-titrations.
Therapeutic response is usually seen after 2-4 weeks of treatment.
After consolidation of the anti
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation bulgare 27-08-2015
Notice patient Notice patient espagnol 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation espagnol 27-08-2015
Notice patient Notice patient tchèque 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation tchèque 27-08-2015
Notice patient Notice patient danois 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation danois 27-08-2015
Notice patient Notice patient allemand 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation allemand 27-08-2015
Notice patient Notice patient estonien 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation estonien 27-08-2015
Notice patient Notice patient grec 16-08-2022
Notice patient Notice patient français 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation français 27-08-2015
Notice patient Notice patient italien 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation italien 27-08-2015
Notice patient Notice patient letton 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation letton 27-08-2015
Notice patient Notice patient lituanien 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation lituanien 27-08-2015
Notice patient Notice patient hongrois 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation hongrois 27-08-2015
Notice patient Notice patient maltais 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation maltais 27-08-2015
Notice patient Notice patient néerlandais 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation néerlandais 27-08-2015
Notice patient Notice patient polonais 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation polonais 27-08-2015
Notice patient Notice patient portugais 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation portugais 27-08-2015
Notice patient Notice patient roumain 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation roumain 27-08-2015
Notice patient Notice patient slovaque 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation slovaque 27-08-2015
Notice patient Notice patient slovène 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation slovène 27-08-2015
Notice patient Notice patient finnois 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation finnois 27-08-2015
Notice patient Notice patient suédois 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation suédois 27-08-2015
Notice patient Notice patient norvégien 16-08-2022
Notice patient Notice patient islandais 16-08-2022
Notice patient Notice patient croate 16-08-2022
Rapport public d'évaluation Rapport public d'évaluation croate 27-08-2015

Rechercher des alertes liées à ce produit

Afficher l'historique des documents